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Abstract Fallopian tube carcinoma isa lethal gynecologic malignancy. Etiologic factors are unknown. No experimental data on molecular alterations 
exist so far. For an in vitro model, we established the permanent human tubal carcinoma cell line FT-MZ- 1. The median doubling time was 14 days 
with 24.2% in S phase. A point missense mutation of the p53 tumor suppressor gene resulting in the His”’ mutant was identified. Aberrant p53 protein 
accumulated in nucleus and cytoplasm. FT-MZ-1 substantially secreted interleukin 6 (11-6) coinciding with the inactivation of p53 as a transrepressor 
on the 11-6 gene promoter. 
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1. Introdllction 
disease comprising 
genital tract [1,2]. 
One-third 
factors are not known; however, low 
conception chronic salpingitis 
develop fallopian 
Only tumor stage has o far been shown to predict prognosis 
[3]. Molecular events such as mutational activation of onco- 
genes or inactivation of tumor suppressor genes associated with 
this cancer have not been reported so far. 
Mutations of the p53 tumor suppressor gene are among the 
most common single-gene alterations associated with human 
malignancy identified so far [4,5]. Inactivation of the ~53 gene 
may contribute to loss of a cell cycle check point at the Gl-S 
boundary and to genetic instability of the cell eventually allow- 
ing cells to replicate in an uncontrolled fashion [6-91. ~53 inac- 
tivation may be induced by different genetic mechanisms lead- 
ing to loss of a complete ~53 allele and/or to subtle intragenic 
mutations both of which have been observed in epithelial ovar- 
ian cancer [lO-161, with similarities to fallopian tube cancer in 
clinical behaviour and management. 
We report on the first permanent cell line established from 
a human fallopian tube carcinoma and on associated molecular 
alterations. The entire ~53 coding region was analyzed for 
mutational inactivation and its effect on ~53 protein expression 
was studied. Interleukin 6 secretion, cytokeratin expression and 
proliferative properties of the cultured cells were determined. 
2. Materials and methods 
2. I. Cell culture 
The cell line FT-MZ-1 was established from the solid primary tumor 
of a FIG0 stage III fallopian tube carcinoma from a 52-year-old patient 
by techniques as previously described [17,18]. The tumor was histopa- 
thologically examined by two independent pathologists (H.E.R. and 
G.D.). FT-MZ-1 cells were kept in Dulbecco’s modified Eagle medium 
*Corresponding author. Fax: (49) (731) 502 6683. 
(DMEM) with 10% fetal calf serum (Gibco) and were analyzed at 
passage 18. Ovarian cancer cell line OV-MZ-7a presenting with a low 
B-6 secretion level served as a control. Breast cancer cell line SK-BR3 
containing the His”’ mutant of the p53 gene was obtained from ATCC. 
Genomic DNA was isolated from the cell lines as well as from fresh 
placental tissue by standard procedures. The DNA sample D263 also 
containing the His”” mutant was a generous gift from S. Baker and 
B. Vogelstein. 
2.2. Growth rate and heterotransplantation 
Doubling time and tumorigenicity were assessed as previously de- 
scribed [18]. 
2.3. Flow cytometry 
FACScan analysis to determine S phase fraction and ploidy was 
carried out as previously described [19]. 
2.4. Analysb of cytokine secretion 
Concentration of 11-6 secreted into the medium was analyzed by a 
solid phase EASIA kit (Medgenix, Bruxelles) after 4 days of log phase 
culture according to the manufacturer’s protocol. 
2.5. Heteroduplex (HD) and single-strand conformation polymorphism 
(SSCP) analysis 
Screening for HD and SSCP as indicators for point mutational 
events was carried out using a high resolution polymer gel (Hydrolink- 
MDE, AT Biochem, Malvem, PA, USA/Serva, Heidelberg, Germany) 
according to manufacturer’s recommendations. PCR primer sequences 
flanking exons 5 to 9 have previously been published [20]. PCR primers 
flanking exons 2 to 3, 4, 10, and 11 @‘-AGAATTCGATCCTCTTG- 
CAGCAGCCAGAW’, S-AACCCTTGTCCITACCAGAAC- 3’, 5’- 
TTTCACCCATCTACAGTCCC-3’, S-ACCTAGGCTCAGGGCA- 
ACTGACCGX, 5’-GGGAATTCAGATCCGTGGGCGTGAG-3’, 
5’-GCTGAGGTCACTCACCTGGA-3’, S’GCTTCTGTCTCCTA- 
CAGCCAC-Y, 5’-ACCTAGGGCTGTCAGTGGGGAACAAGAA- 
G-3’, respectively) were used in addition to screen the entire p53 coding 
region for heteroduplices or SSCPs. Placental DNA sample which 
contained wild-type p53 as previously confirmed by sequencing [21] was 
used as negative control. In heteroduplex analysis, placental DNA 
was also used to identify hemixygous point mutations. Prior to heat- 
denaturation an equal amount of placental PCR product was added to 
allow the formation of a possible heteroduplex between cell line and 
placental DNA strands after slow renaturation controlled by a thermal 
cycler. 
2.6. Multiplex PCR (MPCR) 
The entire protein coding region was PCR amplified using four sets 
of oligonucleotides in a single PCR preparation essentially as described 
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previously [20,21]. Fragments were electrophoresed on a vertical Hy- 
drolink-MDE gel (AT Biochem, Malvern, PA, USAIServa, Heidelberg, 
Germany). 
2.7. Nucleotide sequencing 
For sequence analysis of exon 5 a cycle sequencing strategy was 
applied. For PCR and sequencing reaction priming, the following 
oligonucleotidee were used: Sense primer #O-l27 5’-GGAATTCCA- 
CACCCCCGCCCG-3’ and antisense primer #O-205 5’-CGGA- 
ATTCAGGCGGCTCATAGGGC-3’. For template preparation, PCR 
products were directly purified on a spin column (Centricon-100, Ami- 
con, Beverly, MA, USA). The sequencing reactions were prepared 
according to manufacturer’s recommendations (Cyclist DNA sequenc- 
ing kit, Stratagene, La Jolla, CA, USA) carried out in a thermocycler 
(Minicycler, MJ Research, Watertown, MA, USA) with an initial de- 
naturation step of 3 min at 94°C followed by 30 cycles of 94°C for 30 s, 
54°C for 30 s and 70°C for 1 min. After thermal cvclina. 1 ul of the 
reaction mix was added to 3 ~1 of sequencing stop dolt&n and heat- 
denatured. For electrophoresis and blotting an Autotrans 350 direct 
transfer electrophoresis ystem (Betagen, Waltham, MA, USA) was 
used. One ~1 of the mix was loaded on a 35 cm long 0.2 mm thick 6% 
polyacrylamide gel containing 7.5 M urea. Electrophoresed fragments 
were blotted on N-Nylon membrane (Betagen, Waltham, MA, USA). 
For band visualization Kodak X-omat S film was exposed to the mem- 
brane. 
2.8. PCRIRFLP anatysis 
To confirm a hemizygous or homozygous mutation in codon 175 of 
the p53 gene a PCR/RFLP analysis was applied as previously described 
r221. 
2.9. Immunocytochemistry 
Cells were grown to subconfluency and gently removed from the 
tissue culture dish. Slides were prepared, air-dried and fixed in metha- 
nol (-2O’C) for 4 min and in acetone for 2 min followed by washes in 
PBS. Slides were preincubated in 5% normal horse serum and 3% 
bovine serum albumin diluted in PBS for 30 minutes. p53 was detected 
with the anti-p53 mouse monoclonal antibody PAbl801 by incubation 
at a concentration of 1 &ml for 60 min (Oncogene Science, Manhasset, 
NY, USA). Nonspecific mouse IgG, was used as negative control at the 
same concentration. After three washes with PBS, biotinylated horse 
anti-mouse IgG antibody (1:lOO diluted in 3% bovine serum albumin/ 
PBS) was added and incubated for 60 min. Antibody binding was 
visualized by applying the immunoperoxidase ystem. Slides were then 
dehydrated, cleared in xylene and mounted in permanent coverslipping 
medium. Expression of cytokeratins CK 18, CK 19 and vimentin was 
detected as described previously [ 181. 
3. Results 
FT-MZ-1 cells grew as a monolayer in DMEM with 10% 
fetal calf serum and were analyzed at passage 18. The primary 
tumor site was the left fallopian tube. Metastases were located 
in the right ovary, the broad ligament and the omentum maius. 
Histologically, the tumor presented as an undifferentiated pap- 
illary serous carcinoma. The cultured cells were diploid and had 
an S phase fraction of 24.2% with a median doubling time of 
14 days. FT-MZ-1 did not form tumors after heterotransplan- 
tation of 10’ cells into nude mice. Cytokeratin CK 18 was 
detectable immunocytochemically in 95% of the cell popula- 
tion, CK 19 in 30% and vimentin in 98% (data not shown). High 
level 11-6 secretion was determined at 2051 pg/ml of the cell 
culture supematant. Ovarian control cell line OV-MZ-7a 
showed a secretion level of only 6.6 pg secreted 11-6 per ml of 
the supematant. 
The entire coding region of the ~53 gene was screened for 
mutations by heteroduplex and SSCP analysis. A heteroduplex 
band was observed when the PCR product comprising exon 5 
was mixed with the corresponding PCR product from placental 
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Fig. 1. Nucleotide sequence analysis of exon 5 of the p53 gene. The 
reactions were primed by an antisense oligonucleotide. The left panel 
shows the sequence of FT-MZ-1 with a second base mutation (GTG, 
antisense) in codon 175 (left arrow). The right panel displays the ad- 
type sequence of placental DNA with GCG (antisense) at codon 175 
(right arrow). 
DNA before renaturation (data not shown). PCR fragments 
from all other exons revealed only bands of expected size. In 
SSCP analysis, a band shift was detected in exon 5 when com- 
pared to the correspondent band pattern of the placental PCR 
fragment. Amplification products from all other exons did not 
show an altered band pattern. Sequence analysis of the exon 
5 PCR product revealed a G to A point mutation (sense strand) 
in codon 175 altering a highly conserved arginine residue to a 
histidine (Fig. 1). The observed G to A transition was hemizy- 
gous or homozygous ince no band indicating a G at this posi- 
tion was present. The mutation was confirmed in 3 independent 
experiments tarting from genomic DNA and sequencing with 
a sense and an antisense oligonucleotide primer. The same 
results were obtained analyzing D263 and SK-BR-3 for positive 
control. 
Since sequence analysis suggested that the detected mutation 
in codon 175 was hemizygous or homozygous we applied a 
PCRlRFLP analysis for further confirmation. A 319-bp frag- 
ment encompassing codon 175 was amplified. The HhaI digest 
of the PCR product from the fallopian tube cell line FT-MZ-1 
resulted in a 67 bp band and the complete loss of the 18 bp and 
48 bp bands indicating a hemizygous or homozygous alteration 
of the HhaI recognition palindrome at codon 175 (data not 
shown). The correspondent placental sample showed only the 
wild-type band pattern. Genomic DNA prepared from breast 
cancer cell line SK-BR3 served as a positive control for a 
homozygous mutation in codon 175 [20,23]. 
In immunocytochemical analysis of FT-MZ-1 with PAb 
1801, p53 protein accumulation was found in 75% of the cells. 
Marked staining was observed in the nucleus and in the cyto- 
plasm (Fig. 2). Negative controls using nonspecific mouse IgG 
did not show the described staining. 
LB. Runnebaum et al. IFEBS Letters 353 (1994) 29-32 31 
A 
Fig. 2. Immunocytochemical analysis of p53 expression in F’I-MZ-1. (A) p53-specific monoclonal antibody PAbl801. (B) Negative control. Scale 
marker: 10 pm. 
4. Discussion 
To study molecular events in the carcinogenesis of fallopian 
tube cancer we have established apermanent human tumor cell 
line from a carcinoma of the fallopian tube. To our knowledge, 
no permanent cell lines of this tumor type have been reported. 
FT-MZ-1 was established from a solid tumor of the left fallo- 
pian tube from a 52-year-old patient at FIG0 stage III who had 
not received any neo-adjuvant therapy prior to surgery. The 
tumor was histologically characterized as an undifferentiated 
(grading III) papillary serous carcinoma as 90% of all primary 
fallopian tube cancers [24]. Cytokeratin typing revealed a 
strong expression of cytokeratin CK 18 and CK 19 and also 
vimentin similar to cell lines derived from serous 
adenocarcinoma of the ovary [18]. 
Molecular analyses of the fallopian tube carcinoma have not 
yet been reported. Inactivating mutations of the ~53 tumor 
suppressor gene have been described for numerous human ma- 
lignancies, however not for fallopian tube cancer [4,5]. To ex- 
clude a cell culture artefact archival samples of the parental 
tumor of FT-MZ-1 were analyzed and found to contain the 
same p53 mutation (unpublished observation). The point muta- 
tion described here occurred in codon 175 located in the third 
of five highly conserved domains. Point mutant His175 (Arg to 
His) has been shown to behave as an oncogenic gain-of-func- 
tion mutant able to cooperate in cotransfection with activated 
H-ras in transformation of primary rat embryo fibroblasts [25]. 
His’75 exhibits less sequence-specific and less nonspecific DNA 
binding activity than wild-type ~53 [26,27] and is unable to 
stimulate transcription [28]. Point missense mutations in partic- 
ular codons are selected for in certain tumor types most likely 
for their different properties: hepatocellular carcinoma is asso- 
ciated with a mutational hot spot in codon 249, colorectal 
carcinoma in codons 175, 248 and 273 and lymphoma and 
leukemia in codon 175 [4,5]. Whether codon 175 is a hot spot 
for ~53 mutations in tubal carcinoma is open to further inves- 
tigation. 
FT-MZ-1 cells show a constitutive 11-6 secretion at a high 
level. In an autocrine fashion, 11-6 appears to be implicated in 
proliferation as a stimulatory factor in a number of different 
neoplastic cell types including ovarian cancer cells [29]. Secre- 
tion of 11-6 by the tubal carcinoma cell line FT-MZ-1 may be 
seen in the context of its transcriptionally inactive and homozy- 
gously present mutant ~53. Expression of 11-6 can be regulated 
by wild-type ~53 through repression of the 11-6 gene promoter 
[30,3 11. High 11-6 expression in FT-MZ-1 may be a consequence 
of the loss of p53-induced transcriptional repression. 
~53 His”’ mutant by itself neither appears to convey high 
proliferative potential with a doubling time of 14 days and an 
S phase fraction of 24.2% nor a highly tumorigenic phenotype 
in FT-MZ-1 cells which did not form tumors in nude mice. 
SK-BR3 breast cancer cells containing the same ~53 mutation 
[20] as well have not been found to be highly tumorigenic in 
nude mice [32]. Although His”’ is not associated with a high 
tumorigenic potential it may however represent a decisive step 
in transformation from proliferative oviduct epithelium to inva- 
sive cancer. 
In conclusion, we have established apermanent human fallo- 
pian tube cancer cell line as a model to study molecular steps 
associated with this tumor type of which no experimental data 
have been reported so far. Hot spot point missense mutation 
His”’ leading to ~53 protein accumulation, was identified in 
association with high constitutive 11-6 secretion. In fallopian 
tube cancer ~53 analysis may become helpful in defining pa- 
tients prognosis and in deciding on adjuvant therapeutic on- 
cepts. 
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